9 citations · 10 across the 2 of their papers we have counts for
2 papers
stat.ME2022★ 9 cited
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…
econ.GN2022★ 1 cited
Awareness and use of quantitative decision-making methods in pharmaceutical development
Guido Thömmes, Martin Oliver Sailer, Nicolas Bonnet +3
The pharmaceutical industry has experienced increasing costs and sustained high attrition rates in drug development over the last years. One proposal that addresses this challenge…